DexCom, Inc. DXCM is scheduled to release fourth-quarter 2024 results on Feb. 13, after the closing bell. In the last ...

DexCom (DXCM) shares are down on Monday morning on a notification that some customers are receiving 30 days of supplies instead of 90 days amid ...

G6 continuous glucose monitor (CGM) receivers deliver glucose readings and alerts. However, certain devices may experience an ...

BofA Securities maintained a Buy rating on DexCom (NASDAQ:DXCM) shares, with a steady price target of $90.00. The firm's analysts suggest the current market movement presents an appealing opportunity ...

Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics ...

Key Insights The projected fair value for DexCom is US$123 based on 2 Stage Free Cash Flow to Equity Current share... DexCom (DXCM) doesn't possess the right combination of the two key ingredients ...

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels. However, the rising popularity of GLP-1 drugs ...

Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to ...